Augmenting THerapeutic Effectiveness Through Novel Analytics (ATHENA) - A Public and Private Partnership Project Funded by the Flemish Government (VLAIO).

Data science Distributed analytics Federated platform Machine learning Precision medicine

Journal

Studies in health technology and informatics
ISSN: 1879-8365
Titre abrégé: Stud Health Technol Inform
Pays: Netherlands
ID NLM: 9214582

Informations de publication

Date de publication:
25 May 2022
Historique:
entrez: 25 5 2022
pubmed: 26 5 2022
medline: 27 5 2022
Statut: ppublish

Résumé

The complexity and heterogeneity of cancers leads to variable responses of patients to treatments and interventions. Developing models that accurately predict patient's care pathways using prognostic and predictive biomarkers is increasingly important in both clinical practice and scientific research. The main objective of the ATHENA project is to: (1) accelerate data driven precision medicine for two use cases - bladder cancer and multiple myeloma, (2) apply distributed and privacy-preserving analytical methods/ algorithms to stratify patients (decision support), (3) help healthcare professionals deliver earlier and better targeted treatments, and (4) explore care pathway automations and improve outcomes for each patient. Challenges associated with data sharing and integration will be addressed and an appropriate federated data ecosystem will be created, enabling an interoperable foundation for data exchange, analysis and interpretation. By combining multidisciplinary expertise and tackling knowledge gaps in ATHENA, we propose a novel federated privacy preserving platform for oncology research.

Identifiants

pubmed: 35612220
pii: SHTI220601
doi: 10.3233/SHTI220601
doi:

Types de publication

Journal Article

Langues

eng

Pagination

829-833

Auteurs

Ploingarm Petsophonsakul (P)

Janssen R&D/Clinical Innovation, Belgium.

Ashkan Pirmani (A)

ESAT-STADIUS, KU Leuven, Belgium.

Edward De Brouwer (E)

ESAT-STADIUS, KU Leuven, Belgium.

Murat Akand (M)

Dept. of Urology KU, Belgium.

Wouter Botermans (W)

Janssen R&D/Clinical Innovation, Belgium.

Frank Van Der Aa (F)

Dept. of Urology KU, Belgium.

Joris Robert Vermeesch (JR)

Center for Human Genetics, UZ Leuven, Belgium.

Fritz Offner (F)

Leuven, Dept. of hematology University of Ghent, Belgium.

Roel Wuyts (R)

IMEC, Belgium.

Yves Moreau (Y)

ESAT-STADIUS, KU Leuven, Belgium.

Ingrid Maes (I)

Inovigate, Belgium.

Ines Blockx (I)

Janssen R&D/Clinical Innovation, Belgium.

Patricia Van Rompuy (P)

Janssen BeNeLux, Belgium.

Martine Lewi (M)

Janssen R&D/Clinical Innovation, Belgium.

Bart Vannieuwenhuyse (B)

Janssen BeNeLux, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH